MiMedx Group, Inc (MDXG): Price and Financial Metrics


MiMedx Group, Inc (MDXG)

Today's Latest Price: $6.67 USD

0.04 (-0.60%)

Updated Dec 1 4:00pm

Add MDXG to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

MDXG Stock Price Chart Interactive Chart >

Price chart for MDXG

MDXG Price/Volume Stats

Current price $6.67 52-week high $7.95
Prev. close $6.71 52-week low $2.95
Day low $6.55 Volume 198,900
Day high $6.79 Avg. volume 250,322
50-day MA $6.41 Dividend yield N/A
200-day MA $5.35 Market Cap 740.67M

MiMedx Group, Inc (MDXG) Company Bio

MiMedx Group developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. The company was founded in 2008 and is based in Marietta, Georgia.

Most Popular Stories View All

• 3 Growth Stocks with Considerable Upside Potential

• Investors: We Have Much to Be Thankful For!

• 4 Stocks to Consider Snapping Up as Oil Rebounds

• 3 Terrific Tech Stocks to Buy for Next Year

• Nio vs. Ayro: Which Electric Vehicle Stock is a Better Buy?

View All Top Stories

MDXG Latest News Stream

Event/Time News Detail
Loading, please wait...
View All MDXG News

MDXG Latest Social Stream

Loading social stream, please wait...

View Full MDXG Social Stream

Latest MDXG News From Around the Web

Below are the latest news stories about Mimedx Group Inc that investors may wish to consider to help them evaluate MDXG as an investment opportunity.

MiMedx sees Q3 sales as high as $64M

On a preliminary basis, MiMedx Group (MDXG) expects Q3 sales of $61M - 64M, down 28 - 31% from a year ago although the Q3 2019 sales included a $21.5M benefit from a change in its methods of revenue recognition from the time of cash collection to the time of...

Seeking Alpha | September 21, 2020

MiMedx concludes enrollment for Phase 3 plantar fasciitis trial

MiMedx ([[MDXG]] -0.1%) has completed enrollment in its Phase 3 study of micronized dehydrated Human Amnion Chorion Membrane (dHACM) injection, for plantar fasciitis, an inflammation of the fibrous tissue along the bottom of the foot that results in intense pain.The 276-subject study is designed to provide statistically significant evidence of efficacy for dHACM to reduce...

Seeking Alpha | September 17, 2020

MiMedx Announces Filing of 2020 First Quarter Form 10-Q

Company Now Caught Up in Financial Reporting First Quarter Net Sales of $61.7 million MARIETTA, Ga., July 06, 2020 -- MiMedx Group, Inc. (OTC.

Yahoo | July 6, 2020

MiMedx Announces Filing of 2019 Annual Report

Annual Report on Form 10-K includes Audited Financial Results for 2019 Transition to Revenue Recognition on an “As-Shipped” Basis Reflects Improved Internal Control Environment.

Yahoo | July 6, 2020

MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing of concurrent $150 million private equity and debt financings, consisting of an equity financing pursuant to a Securities Purchase Agreement with an entity controlled by EW Healthcare Partners and certain funds managed by Hayfin Capital Management LLP (“Hayfin”), and a debt financing pursuant to a Loan Agreement with Hayfin. As part of the transaction, EW Healthcare Partners has designated Martin P. Sutter and William A. Hawkins III to serve on the Company’s board as preferred directors.

Yahoo | July 2, 2020

Read More 'MDXG' Stories Here

MDXG Price Returns

1-mo 9.34%
3-mo 1.06%
6-mo 90.57%
1-year -7.36%
3-year -42.30%
5-year -25.89%
YTD -12.01%
2019 323.46%
2018 -85.80%
2017 42.33%
2016 -5.44%
2015 -18.73%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9897 seconds.